Paper Details

  1. Home
  2. Paper Details

Abacavir-based Regimen for HIV-infected Children and Adolescents.

Author: MauryaManisha, PareekPrince, RaiRuchi, SinghD K, SrivastavaAnubha

LetterA written message for communication and exchange of information between individuals.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

This study investigated the side effects and failure rates of abacavir-based HAART regimen in 48 children over a year. The study found no hypersensitivity reactions and a significant improvement in CD4 count, while the failure rate was 14.5%.
Paper Details　
Original Abstract of the Article :
We studied 48 children receiving abacavir-based HAART regimen, over a period of one-year for side effects and failure rates. None of the children developed hypersensitivity reaction. The CD4 count significantly improved from the time of enrolment till 12 months of therapy while the failure rate was ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31477651

データ提供：米国国立医学図書館（NLM）

Abacavir: A Reliable Camel in the HIV Treatment Oasis

This research explores the effectiveness and safety of abacavir-based highly active antiretroviral therapy (HAART) regimen in children and adolescents living with HIV. The study tracked 48 children over a year, assessing their CD4 count and failure rates. The results highlight the efficacy of abacavir in improving CD4 counts and demonstrating a relatively low failure rate. The study's findings are akin to finding a fertile oasis in the challenging desert of HIV treatment.

A Beacon of Hope in the Treatment of HIV in Children

This research demonstrates the efficacy and safety of abacavir-based HAART in children and adolescents living with HIV. The study's findings offer a beacon of hope for improving the lives of these young patients.

Navigating the Path to a Healthier Future for Children with HIV

The effectiveness of abacavir in improving CD4 counts and achieving a low failure rate provides a valuable tool for managing HIV in children. This research offers hope for improving the health and well-being of children living with HIV.

Dr.Camel's Conclusion

This study sheds light on the promise of abacavir-based HAART regimens in children and adolescents living with HIV. The positive outcomes observed in this research, like finding a cool oasis in the desert, offer hope for a brighter future for young patients. This discovery is a testament to the ongoing efforts in HIV research and highlights the importance of finding effective treatment options for all patients.

Date :
  1. Date Completed 2020-03-16
  2. Date Revised 2020-03-16
Further Info :

Pubmed ID

31477651

DOI: Digital Object Identifier

31477651

Related Literature

Article Analysis
・Side Effects of abacavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.